News

First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis

Three U.S. clinical trial sites actively screening and enrolling patients; Topline data expected by mid-2023BOCA RATON, Fla., March 10, 2023…

2 years ago

Aseptic Filling of Small Volumes at High Precision

Filling accuracy has become increasingly important for laboratories and biopharmaceutical manufacturers. Single Use Support has developed best-in-class filling precision for…

2 years ago

Independent Study of Fully Virtual TeleOUD Model Finds Patients Report High Satisfaction and Positive Experiences with Care

Peer-reviewed research, published in the Journal of Addiction Medicine, shows feedback from Bicycle Health patients indicating the positive impacts of…

2 years ago

New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare

92 percent of doctors in the U.S. say genetics is an important part of a patient’s complete health picture66 percent…

2 years ago

UpHealth, Inc. Announces $4.5 Million Private Placement

DELRAY BEACH, Fla., March 09, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc. (“UpHealth” or the “Company”) (NYSE: UPH), a global digital…

2 years ago

ICU Medical to Participate at the KeyBanc Life Sciences & MedTech Investor Forum

SAN CLEMENTE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and…

2 years ago

Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision…

2 years ago

Predictive Oncology Issues Letter to Shareholders

Signature of Raymond F. Vennare, Chief Executive Officer Signature of Raymond F. Vennare, Chief Executive OfficerEAGAN, Minn., March 09, 2023…

2 years ago

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Qualigen Therapeutics, Inc. F3 Compounds Cooperate with Checkpoint Inhibitors and Other RAS Inhibitors Qualigen Therapeutics, Inc. F3-8-60 inhibits RAS RAF…

2 years ago